Home > News > Recent cases

Teva v Novartis [2022] EWHC 2779 (Ch)19 October 2022Justin Turner KC represented Claimants (“Teva”) seeking an Arrow declaration in relation to fingolimod to treat relapsing-remitting multiple sclerosis at a particular dosage in order to clear out of the way a patent belonging to the Defendant (“Novartis”). After the proceedings commenced but before trial, Novartis withdrew the UK designation of its European patent. Bacon […]
John Lobb Ltd v John Lobb SAS [2022] EWHC 2306 (Ch)8 September 2022Jaani Riordan (led by Huw Davies KC of Essex Court Chambers) appeared for the Defendant/Appellant (“JLSA”), a wholly owned subsidiary of Hermès, in its successful appeal seeking summary dismissal of a claim brought by an English company (“JLL”).  JLL had sought to set aside a 2008 agreement between JLL and JLSA on the basis that […]
IBM UK Ltd v LzLabs GmbH & Ors [2022] EWHC 2094 (TCC)5 August 2022Jaani Riordan appeared as junior counsel in an application for an interim antisuit injunction to restrain the Claimant (“IBM UK”) and its US parent company (“IBM Corp”) from continuing parallel proceedings in Texas and joining IBM Corp as a party to the proceedings in England and Wales.  IBM Corp applied to set aside service under […]
Shenzhen Carku Technology Co v The Noco Company [2022] EWHC 2034 (Pat)4 August 2022James Abrahams QC appeared as lead counsel for the Defendant (“NOCO”) in proceedings brought by the Claimant (“Carku”) to revoke NOCO’s patent for lack of novelty and inventive step.  Carku brought a further claim for damages, alleging NOCO had made groundless threats to Amazon through its UK complaints procedure in relation to Carku’s listed products.  […]
Sandoz & Anr v Bristol-Myers Squibb & Ors [2022] EWHC 1831 (Pat)15 July 2022Andrew Lykiardopoulos QC appeared for Sandoz and Justin Turner QC appeared for Teva  in proceedings to invalidate 4 patents owned by Bristol-Myers Squibb (“BMS”) and Pfizer, both of whom counterclaimed that the generic products which Sandoz and Teva intended to launch on the UK market would infringe. The patents related to a formulation of apixaban […]